Cited by 413Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Open access

Tebbutt, Niall C., Wilson, Kate, Gebski, Val J., Cummins, Michelle M., Zannino, Diana, van Hazel, Guy A., Robinson, Bridget, Broad, Adam, Ganju, Vinod, Ackland, Stephen P., Forgeson, Garry, Cunningham, David, Saunders, Mark P., Stockler, Martin R., Chua, YuJo, Zalcberg, John R., Simes, R. John, Price, Timothy J.·2010·Journal of Clinical Oncology

DOI 10.1200/jco.2009.27.7723

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial. Patients and Methods: Overall, 471 patients in Australia, New Zealand, and the United Kingdom with previously untreated, unresectable mCRC were randomly assigned to the following: capecitabine; capecitabine plus bevacizumab (CB); or capecitabine, bevacizumab, and mitomycin (CBM). We compared CB with capecitabine and CBM with capecitabine for progression-free survival (PFS). Secondary end points included overall survival (OS), toxicity, response rate (RR), and quality of life (QOL). Results: Median PFS was 5.7 months for capecitabine, 8.5 months for CB, and 8.4 months for CBM (capecitabine v CB: hazard ratio [HR], 0.63; 95% CI, 0.50 to 0.79; P < .001; C v CBM: HR, 0.59; 95% CI, 0.47 to 0.75; P < .001). After a median follow-up of 31 months, median OS was 18.9 months for capecitabine and was 16.4 months for CBM; these data were not significantly different. Toxicity rates were acceptable, and all treatment regimens well tolerated. Bevacizumab toxicities were similar to those in previous studies. Measures of overall QOL were similar in all groups. Conclusion: Adding bevacizumab to capecitabine, with or without mitomycin, significantly improves PFS without major additional toxicity or impairment of QOL.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.27.7723

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Self-citation
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
Kabbinavar, F. F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Liebérman, G., Griffing, S., & Bergsland, E. K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,711
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,596
Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H. P., Miller, K. D., Kabbinavar, F. F., Bergsland, E. K., Ngai, J., Holmgren, E. B., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 940

Flagged first, then by citations

Show all 20 references

Research works printed but not linked: 2

Presta LG, 1997, Cancer Res, 57, 4593
Wagner AD, 2009, Cochrane Database Syst Rev, 3, CD005392

Sorted by citations

Items 201–300 of 413

How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?
Bronte, G., Rolfo, C. D., Peeters, M., & Russo, A. D. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.902926 · Cited by 15
Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study)
Nishina, T., Moriwaki, T., Shimada, M., Higashijima, J., Sakai, Y., Masuishi, T., Ozeki, M., Amagai, K., Negoro, Y., Indo, S., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.12.001 · Cited by 15
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013
Price, T. J., Segelov, E., Burge, M., Haller, D. G., Tebbutt, N. C., Karapetis, C. S., Punt, C. J. A., Pavlakis, N., Arnold, D., Gibbs, P., et al. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.949678 · Cited by 13
Self-citation
Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis
Ridouane, Y., Lopes, G. D. L., Jr., Ku, G. Y., Masud, H., & Haaland, B. A. (2017) · Oncotarget · doi:10.18632/oncotarget.20185 · Cited by 13
Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Mooi, J. K., Chionh, F. J. M., Savas, P. S., Duarte, J. D. G., Chong, G., Brown, S. C., Wong, R., Price, T. J., Wann, A., Skrinos, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2714 · Cited by 17
Self-citation
Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study
Stein, A., Quidde, J., Schröder, J., Göhler, T., Tschechne, B., Valdix, A.-R., Höffkes, H., Schirrmacher-Memmel, S., Wohlfarth, T., Hinke, A., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2113-8 · Cited by 15
Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2
Tu, M., Lu, C., Lv, N., Wei, J., Lu, Z., Xi, C., Chen, J., Guo, F., Jiang, K., Li, Q., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.09.031 · Cited by 14
Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer
Ruan, W., Che, Y.-P., Ding, L., & Li, H. (2019) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207322666190119162352 · Cited by 14
Cancer research in the global village
Munro, A. J., & Niblock, P. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61022-7 · Cited by 14
Xeliri Plus Bevacizumab Compared with Folfiri Plus Bevacizumab as First-Line Setting in Patients with Metastatic Colorectal Cancer: Experiences at Two-Institutions
Uygun, K., Bilici, A. E., Kaya, S., Ustaalıoğlu, B. B. Ö., Yıldız, R., Temiz, S., Şeker, M., Aksu, G., Çabuk, D., & Gümüş, M. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.4.2283 · Cited by 13
Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective
Zhang, P., Wen, F., Zhou, J., Huang, J.-X., Zhou, K.-X., Wu, Q., Wang, X., Zhang, M.-X., Liao, W.-T., & Li, Q. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02114-x · Cited by 13
Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer
Lim, S. H., Cho, H. T., Kim, K., Lim, H. Y., Kang, W. K., LEE, J., PARK, Y. S., Kim, H. C., & Kim, S. T. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.030374 · Cited by 12
Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients
Aprile, G. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i46.8474 · Cited by 11
Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5‐fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer
Shigeta, K., Hasegawa, H., Okabayashi, K., Tsuruta, M., Ishii, Y., Endo, T., Ochiai, H., Kondo, T., & Kitagawa, Y. (2016) · International Journal of Cancer · doi:10.1002/ijc.30127 · Cited by 12
The changing face of treatment for metastatic colorectal cancer
Pfeiffer, P., Köhne, C.-H., & Qvortrup, C. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1543593 · Cited by 12
Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?
Strickler, J. H., & Hurwitz, H. I. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0363-z · Cited by 12
Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
Bruera, G., Cannita, K., Giordano, A. V., Vicentini, R., Ficorella, C., & Ricevuto, E. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2369 · Cited by 12
Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials
Hofheinz, R., Ronellenfitsch, U., Kubicka, S., Falcone, A., Burkholder, I., & Hacker, U. T. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/9189483 · Cited by 12
Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials
Goey, K. K. H., Elias, S. G., Hinke, A., van Oijen, M. G. H., Punt, C. J. A., Hegewisch‐Becker, S., Arnold, D., & Koopman, M. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.382 · Cited by 12
Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives
Jacobsen, A., Siebler, J., Grützmann, R., Stürzl, M., & Naschberger, E. (2024) · Cancers · doi:10.3390/cancers16050890 · Cited by 11
VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types—A Meta-Analysis
Conway, J. W., Braden, J., Lo, S., Scolyer, R. A., Carlino, M. S., Menzies, A. M., Long, G. V., & da Silva, I. P. (2023) · Cancers · doi:10.3390/cancers15205012 · Cited by 11
Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis
Rosa, B. R., de Jesus, J. P., de Mello, E. L., Cesar, D. S., & Correia, M. M. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.582 · Cited by 11
Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives
Bekaii‐Saab, T., Bupathi, M., & Ahn, D. H. (2016) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s97740 · Cited by 13
Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer
Claassen, Y. H. M., van der Valk, M. J. M., Breugom, A. J., Frouws, M. A., Bastiaannet, E., Liefers, G., van de Velde, C. J., & Kapiteijn, E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012326.pub2 · Cited by 11
The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study
Lee, B., Wong, H., TACEY, M. A., Tie, J., Wong, R., Lee, M., Nott, L. M., Shapiro, J. D., Jennens, R. R., Turner, N. H., et al. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12639 · Cited by 11
Ramucirumab: the long and winding road toward being an option for mCRC treatment
Debeuckelaere, C., Murgioni, S., Lonardi, S., Girardi, N., Alberti, G., Fano, C., Gallimberti, S., Magro, C., Djaballah, S. A., Daniel, F., et al. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1600505 · Cited by 11
Can we accurately report PTEN status in advanced colorectal cancer?
Hocking, C. M., Hardingham, J. E., Broadbridge, V. T., Wrin, J., Townsend, A. R., Tebbutt, N. C., Cooper, J. E., Ruszkiewicz, A. R., Lee, C. K., & Price, T. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-128 · Cited by 12
Self-citation
Quantification of Patient-Specific Assay Interference in Different Formats of Enzyme-Linked Immunoassays for Therapeutic Monoclonal Antibodies
Grebenchtchikov, N. I., Geurts-Moespot, A. J., Heijmen, L., van Laarhoven, H. W. M., van Herpen, C. M. L., Thijs, A. M. J., Span, P. N., & Sweep, F. C. G. J. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000090 · Cited by 11
Personalized Treatment of Colorectal Cancer
Arnold, D., & Stein, A. (2012) · Onkologie · doi:10.1159/000334821 · Cited by 11
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
Giessen, C. A., von Weikersthal, L. F., Hinke, A., Stintzing, S., Kullmann, F., Vehling‐Kaiser, U., Mayerle, J. V., Bangerter, M., Denzlinger, C., Sieber, M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-367 · Cited by 11
Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer andCXCL5expression: Six case reports
Novillo, A., Gaibar, M., Romero‐Lorca, A., Gilsanz, M. F., Beltrán, L., Galán, M. Á., Antón-Pascual, B., Malón, D., Moreno, A., & Fernández‐Santander, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i16.1979 · Cited by 11
Prognostic Effect of Performance Status on Outcomes of Patients with Colorectal Cancer Receiving First-Line Chemotherapy: A Meta-analysis
Colloca, G. A., & Venturino, A. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-00983-8 · Cited by 10
Management of Elderly Colorectal Cancer Patients: A Comprehensive Review Encompassing Geriatric Assessment
Boccaccino, A., Cassaniti, M., Rossini, D., Faccani, L., Casadio, C., & Tamberi, S. (2025) · Cancers · doi:10.3390/cancers17203336 · Cited by 10
Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer
Adamowicz, K., Saad, E. D., & Jassem, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.015 · Cited by 10
Identification and Validation of Immune Molecular Subtypes and Immune Landscape Based on Colon Cancer Cohort
Qi, W., & Zhang, Q. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.827695 · Cited by 10
In colon cancer cells fascin1 regulates adherens junction remodeling
Esmaeilniakooshkghazi, A., Pham, E., George, S. P., Ahrorov, A., Villagómez, F. R., Byington, M. C., Mukhopadhyay, S., Patnaik, S., Conrad, J. C., Naik, M., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202201454r · Cited by 9
Self-citation
Safety of first-line systemic therapy in patients with metastatic colorectal cancer: a network meta-analysis of randomized controlled trials
Zhan, Y., Cheng, X., Mei, P., Tan, S., Feng, W., & Jiang, H. (2024) · BMC Cancer · doi:10.1186/s12885-024-12662-3 · Cited by 10
Analysis of Clinical End Points of Randomised Trials Including Bevacizumab and Chemotherapy versus Chemotherapy as First-line Treatment of Metastatic Colorectal Cancer
Colloca, G. A., Venturino, A., & Guarneri, D. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.05.001 · Cited by 10
TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer
Hsu, H., You, J., Chen, S., Chen, H., Yeh, C.-Y., Tsai, W., Hung, H., Yang, T., Lapke, N., & Tan, K. T. (2019) · Cancers · doi:10.3390/cancers11081079 · Cited by 10
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer
Strickler, J. H., Rushing, C. N., Niedzwiecki, D., McLeod, A., Altomare, I. P., Uronis, H. E., Hsu, S. D., Zafar, S. Y., Morse, M. A., Chang, D. Z., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6234-8 · Cited by 10
Colorectal cancer peritoneal metastases: Biology, treatment and next steps
Baaten, I. C. P. A., West, N. P., Quyn, A. J., Seymour, M., & Seligmann, J. F. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.10.035 · Cited by 10
Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
Kristin, E., Endarti, D., Khoe, L. C., Taroeno‐Hariadi, K. W., Trijayanti, C., Armansyah, A., & Sastroasmoro, S. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.6.1921 · Cited by 10
SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome
Liao, X., Huang, L., Yu, Q., He, S., Li, Q., Huang, C., & Yuan, X. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04053-9 · Cited by 9
Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial
Ferreira, C. S., Babitzki, G., Klaman, I., Krieter, O., Lechner, K., Bendell, J. C., Harring, S. V., & Heil, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1157596 · Cited by 9
Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer
Otsu, S., & Hironaka, S. (2023) · Cancers · doi:10.3390/cancers15184564 · Cited by 9
Optimal duration of systemic treatment in metastatic colorectal cancer
Simkens, L. H. J., Koopman, M., & Punt, C. J. A. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000087 · Cited by 9
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C 3 ) study
Nagasaka, T., Mishima, H., Sawaki, A., Shimokawa, M., Inukai, M., Shinozaki, K., Tanioka, H., Nasu, J., Nishina, T., Hazama, S., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011454 · Cited by 10
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer
Elia, E. G., Städler, N., Ciani, O., Taylor, R. S., & Bujkiewicz, S. (2020) · Cancer Epidemiology · doi:10.1016/j.canep.2019.101665 · Cited by 9
Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
Riechelmann, R. P., Peixoto, R. D., Fernandes, G. D. S., Weschenfelder, R. F., Prolla, G., Filho, D. R., Andrade, A. C., Crosara, M. A. T., Rêgo, J. F. M., Gansi, R. C., et al. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1048 · Cited by 9
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
Sommerhäuser, G., Kurreck, A., Stintzing, S., Heinemann, V., von Weikersthal, L. F., Dechow, T. N., Kaiser, F., Karthaus, M., Schwaner, I., Fuchs, M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09892-8 · Cited by 9
Gastric cancer: past progress and present challenges
Sjoquist, K. M., & Zalcberg, J. R. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0437-0 · Cited by 9
Self-citation
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Razenberg, L. G. E. M., van Gestel, Y. R. B. M., de Hingh, I. H. J. T., Loosveld, O. J. L., Vreugdenhil, G., Beerepoot, L. V., Creemers, G. J. M., & Lemmens, V. E. P. P. (2016) · BMC Cancer · doi:10.1186/s12885-016-2158-8 · Cited by 9
Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database
Margalit, O., Harmsen, W. S., Shacham‐Shmueli, E., Voss, M. M., Boursi, B., Wagner, D., Cohen, R., Olswold, C. L., Saltz, L. B., Goldstein, D. A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.10.022 · Cited by 8
Self-citation
Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?
Cheung, M. C., Chan, K., Sabharwal, M., Fields, A. L. A., Chambers, A., & Evans, W. K. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000124 · Cited by 8
Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
Rossi, L., Zoratto, F., Zullo, A., Papa, A., Zaccarelli, E., Giordani, E., Baiano, G., Colonna, M., Tomao, L., & Tomao, S. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s30581 · Cited by 8
Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials
Yin, G., & Zhao, L. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.1947022 · Cited by 9
Biologic Therapies in Colorectal Cancer: Indications and Contraindications
Fakih, M. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e197 · Cited by 9
Polymerase Chain Reaction: Types, Utilities and Limitations
Hernández-Rodríguez, P., & Gomez, A. P. (2012) · InTech eBooks · doi:10.5772/37450 · Cited by 9
Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain
Marín-Pozo, J. F., Duarte, J., & Sánchez‐Rovira, P. (2016) · Medicine · doi:10.1097/md.0000000000003623 · Cited by 8
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors
Wang, F., Molina, J. R., Satele, D., Yin, J., Lim, V.-S., & Adjei, A. A. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0690-x · Cited by 8
MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer
Camera, S., Deleporte, A., Bregni, G., Trevisi, E., Pretta, A., Telli, T. A., Polastro, L., Gombos, A., Kayumba, A., Ameye, L., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.05.007 · Cited by 8
Personalized Treatment is Better than one Treatment Fits All in the Management of Patients with mCRC: A Consensus Statement
Yalçın, Ş., Trad, D., Kader, Y. A., Halawani, H., Demir, O. G., Mall, R., Meshcheryakov, A., Nasr, F. L., Nosworthy, A. L., Osinsky, D., et al. (2014) · Future Oncology · doi:10.2217/fon.14.203 · Cited by 8
Is the Postprogression Survival Time Really Not Shortened in the Bevacizumab-Containing Arms of Phase III Clinical Trials?
Potemski, P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0158 · Cited by 8
Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome
Wongkraisri, C., Chusuwanrak, K., Laocharoenkeat, A., Chularojanamontri, L., Nimmannit, A., & Ithimakin, S. (2025) · BMC Cancer · doi:10.1186/s12885-025-13684-1 · Cited by 7
First-line molecular therapies in the treatment of metastatic colorectal cancer – a literature-based review of phases II and III trials
Vogel, A., & Kirstein, M. M. (2018) · Innovative Surgical Sciences · doi:10.1515/iss-2018-0012 · Cited by 7
Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab
Roohullah, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i17.5352 · Cited by 8
The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement
Abrahão, A. B. K., Karim, S., Colwell, B., Berry, S. R., & Biagi, J. J. (2017) · Current Oncology · doi:10.3747/co.24.3757 · Cited by 7
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement
Fountzilas, E., Krishnan, E., Jankú, F., Fu, S., Karp, D. D., Naing, A., Subbiah, V., Hong, D. S., Piha-Paul, S. A., Vining, D. J., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3680-y · Cited by 7
Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach
Heijmen, L., Punt, C. J. A., ter Voert, E. E. G. W., de Geus‐Oei, L., Heerschap, A., Bussink, J., Sweep, F. C. G. J., Zerbi, V., Oyen, W. J. G., Span, P. N., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9920-9 · Cited by 7
Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta‐analysis
Wang, J., Luo, L., Wang, D., Guo, B., Li, J., Zhu, Y., & Tang, D. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26312 · Cited by 8
Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study)
Kurreck, A., Heinemann, V., von Weikersthal, L. F., Decker, T. W., Kaiser, F., Uhlig, J., Schenk, M., Freiberg‐Richter, J., Peuser, B., Denzlinger, C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.010 · Cited by 7
Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer
Gaibar, M., Galán, M., Romero‐Lorca, A., Antón-Pascual, B., Malón, D., Moreno, A., Fernández‐Santander, A., & Novillo, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031381 · Cited by 7
The impact of infusion reactions associated with monoclonal antibodies in metastatic colorectal cancer: A European perspective
Chadda, S., Larkin, M., Jones, C., Sykes, D., Barber, B., Zhao, Z., Gao, S., & Bengttson, N.-O. (2012) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212451197 · Cited by 7
Does the addition of targeted biological agents to first‐line chemotherapy for advanced colorectal cancer increase complete response? A systematic review and meta‐analysis
Qi, W., Shen, Z., Tang, L., & Yao, Y. (2014) · Colorectal Disease · doi:10.1111/codi.12647 · Cited by 6
Innovations in colorectal cancer treatment: trifluridine and tipiracil with bevacizumab for improved outcomes – a review
Rais, T., Riaz, R., Siddiqui, T., Shakeel, A., Khan, A., & Zafar, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1296765 · Cited by 9
The efficacy and safety of panitumumab supplementation for colorectal cancer
Wang, C., Tan, C.-Y., Chen, X., & Chen, S. (2020) · Medicine · doi:10.1097/md.0000000000019210 · Cited by 6
Is there an efficacy-effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer: a systematic review and meta-analysis
Zhang, X., Fu, S., Meng, R., Ren, Y., Shang, Y., & Tian, L. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-2303 · Cited by 4
Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer
Li, J., Cai, Y., & Deng, Y. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00852-1 · Cited by 6
Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer
Punt, C. J. A., Kwakman, J. J. M., Mol, L., Roodhart, J. M. L., Hendriks, M. P., Speetjens, F. M., Iersel, L. V., Trajkovic, M., Spierings, L. E. A. M. M., Helgason, H. H., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.02.004 · Cited by 6
Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis
Wang, M., Zheng, X., Ruan, X., Bailiang, Y., Cai, L., Feizhuan, L., Jinfu, T., Jiang, F., & Shaotang, L. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20132241 · Cited by 6
Cost-Effectiveness of Gene-Expression Profiling for Tumor-Site Origin
Hornberger, J. C., Degtiar, I., Gutierrez, H. R., Shewade, A., Henner, W. D., Becker, S. H., Varadachary, G., & Raab, S. S. (2013) · Value in Health · doi:10.1016/j.jval.2012.09.005 · Cited by 6
Traitements anti-angiogéniques dans le cancer colorectal métastatique : peut-on envisager un blocage continu de l’angiogenèse ?
Jary, M., Borg, C., Bouché, O., Kim, S. C. H., André, T., & Bennouna, J. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.05.002 · Cited by 9
A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
Wentink, M. Q., Broxterman, H. J., Lam, S. W., Boven, E., Walraven, M., Griffioen, A. W., Пили, Р., van der Vliet, H. J., de Gruijl, T. D., & Verheul, H. M. W. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.275 · Cited by 6
Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
Baek, S. K., Lee, K. T., Bae, S. B., & Lee, S. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.071 · Cited by 6
Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer
Yoshida, Y., Kaneko, M., & Narukawa, M. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01619-8 · Cited by 6
Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06)
Matter-Walstra, K. W., Schwenkglenks, M. M., Betticher, D. C., von Moos, R., Dietrich, D., Baertschi, D., & Koeberle, D. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.03.002 · Cited by 6
Risk of Serious Neutropenic Events in Cancer Patients Treated with Bevacizumab: A Meta-analysis
Zhou, F., Shao, J., Wu, L., Yin, X., & Yu, X. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.4.2453 · Cited by 6
Cancer-associated fibroblasts expressing FSTL3 promote vasculogenic mimicry formation and drive colon cancer malignancy
Ying, L., Zhu, Y., Zhang, L., Ji, M., Wang, M., Dong, L., Yun, Z., Chen, Y., Zhou, J., Huang, C., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08009-w · Cited by 5
Antiangiogenic Therapy of Colorectal Cancer: State of the Art, Challenges and New Approaches
Sarmiento, R., Longo, R., & Gasparini, G. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.10441 · Cited by 5
Increasing age-related survival gap among patients with colorectal cancer: a population-based retrospective study
Feng, Y., Mo, S., Dai, W., Li, Q., Cai, G., & Cai, S. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01538-3 · Cited by 5
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis
Yin, J., Dawood, S. S., Cohen, R., Meyers, J., Zalcberg, J. R., Yoshino, T., Seymour, M., Maughan, T., Saltz, L. B., Cutsem, E. V., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211020547 · Cited by 5
Self-citation
Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
Bartolomeo, M. D., Maggi, C., Ricchini, F., Pietrantonio, F., Iacovelli, R., de Braud, F., & Inno, A. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s54675 · Cited by 5
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019
Lau, D. K., Burge, M., Roy, A. C., Chau, I., Haller, D. G., Shapiro, J. D., Peeters, M., Pavlakis, N., Karapetis, C. S., Tebbutt, N. C., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744439 · Cited by 5
Self-citation
Second‐line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild‐type KRAS
Hong, Y. S., Kim, H. J., Park, S., Kim, K., Lee, J., Park, J., Kim, J. H., Lim, S., Yu, C. S., Kim, J. C., et al. (2013) · Cancer Science · doi:10.1111/cas.12098 · Cited by 5
Bevacizumab Plus Chemotherapy in Metastatic Colorectal Cancer Patients Treated in Clinical Practice
Rossi, L., Veltri, E. M., Zullo, A., Zoratto, F., Colonna, M., Seri, M. D., Longo, F., Mottolese, M., Giannarelli, D., Ruco, L., et al. (2012) · Future Oncology · doi:10.2217/fon.12.108 · Cited by 5
Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland
Chapman, S., McKavanagh, D., Burge, M., McPherson, I., Walpole, E. T., & Hollingworth, S. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12518 · Cited by 5
Time for a Level Playing Field: Inequalities in Regulatory/Approval Processes—The Example of Bevacizumab in Epithelial Ovarian Cancer
Hoskins, P. J., Fung‐Kee‐Fung, M., Miller, D. M., & Gotlieb, W. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3690 · Cited by 5
Vascular Disruption Therapy as a New Strategy for Cancer Treatment
Gómez-Escudero, J., Berlana-Galán, P., Guerra-Paes, E., Torre-Cea, I., Marcos-Zazo, L., Carrera-Aguado, I., Cáceres-Calle, D., Sánchez‐Juanes, F., & Muñoz‐Félix, J. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010085 · Cited by 7
The discovery of Bevacizumab. An historical reappraisal
Ribatti, D. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01857-y · Cited by 4
Efficacy and safety of first-line targeted and immunotherapy for metastatic colorectal cancer: a network meta-analysis
Huo, L., Yue, H., Yang, R., Sun, X., Wang, Z., Liu, H., Liu, J., Feng, R., & Liang, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643133 · Cited by 4

Authors: Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., Robinson, B., Broad, A., Ganju, V., Ackland, S. P., Forgeson, G., Cunningham, D., Saunders, M. P., Stockler, M. R., Chua, Y., Zalcberg, J. R., Simes, R. J., & Price, T. J.
Affiliations: The University of Sydney (AU)
From Austin Health; Peter MacCallum Cancer Centre; Frankston Hospital, Melbourne; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney; Sir Charles Gairdner Hospital, Perth; Geelong Hospital, Geelong; Canberra Hospital, Canberra; Queen Elizabeth Hospital, Adelaide; Calvary Mater Newcastle Hospital, Newcastle, Australia; Royal Marsden Hospital, London; Christie Hospital, Manchester, United Kingdom; Christchurch Hospital, Christchurch; and Palmerston North...
ORCID: Tebbutt, Niall C.
Wilson, Kate
Gebski, Val J.
Cummins, Michelle M.
Zannino, Diana
Robinson, Bridget
Ganju, Vinod
Ackland, Stephen P.
Cunningham, David
Saunders, Mark P.
Stockler, Martin R.
Zalcberg, John R.
Simes, R. John
Price, Timothy J.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2010-07-01
Volume: 28
Issue: 19
Pages: 3191-3198
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.27.7723
OpenAlex: W2122152991
Cited by: 413
References: 20
Citations by year: 2026: 4 · 2025: 11 · 2024: 18 · 2023: 19 · 2022: 15 · 2021: 19 · 2020: 25 · 2019: 23 · 2018: 23 · 2017: 29 · 2016: 45 · 2015: 39 · 2014: 39 · 2013: 47 · 2012: 28
FWCI: 16.42
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
UWA Profiles and Research Repository (UWA) (submittedVersion)
Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
NOVA (University of Newcastle Australia) (submittedVersion)
Funders: National Institute for Health and Care Research (NF-SI-0507-10154)
Cancer Australia
Cancer Institute NSW
National Health and Medical Research Council
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, capecitabine, bevacizumab, mitomycin C, first-line chemotherapy, progression-free survival, overall survival, quality of life, treatment toxicity, anti-VEGF therapy
MeSH terms: Bevacizumab, Capecitabine, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Diarrhea, Female, Fluorouracil, Humans, Hypotension, Male, Middle Aged, Neoplasm Metastasis, Quality of Life, Thrombocytopenia, Colorectal Neoplasms, Mitomycin, Treatment Outcome, Australasia, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks